NEW YORK—Covington represented Lantheus Holdings, Inc. in its definitive agreement under which Lantheus will merge with a wholly-owned subsidiary of Curium US Holdings. The transaction represents a total per share consideration of up to $114.50 and a total transaction value of up to approximately $8.0 billion.
Under the terms of the definitive agreement, Curium US will acquire all of the outstanding shares of Lantheus for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights providing for up to $12.00 per share in potential additional cash payments, subject to achievement of specified commercial milestones for Lantheus’ products through 2030.
Lantheus is a leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight, and Follow® disease to deliver better patient outcomes
Curium is a leading, global radiopharmaceutical company with proven expertise in the development, manufacturing and supply of radiopharmaceuticals that improve the way cancer is diagnosed and treated.
The Covington team included Jack Bodner, Andrew Ment, Jason Yu, Louise Lu, and Ben Sovocool (M&A), Kerry Burke, Brianna Bloodgood, and Libby Brown (securities and capital markets), Van Ellis, Natalie Oveyssi, Oliver Hodgkiss, and Billy Wu (licensing), Peter Schwartz and Jennifer Uren (finance), Michael Stern, Dalia Deak, and Deepen Gagneja (regulatory, U.S.), Sarah Cowlishaw and Daniel Spivey (regulatory, EU), Ansgar Simon (tax), Jenna Wallace, James Damon, and Montené Speight (employment), Libbie Canter and Clare Mathias (privacy), Thomas Brugato (environmental), Stefanie Doebler (healthcare), Seth Atkisson (trade control), and Mona Patel (anti-corruption).
Back
